Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Syngenta acquires genetic repository from Novartis to boost biologic crop protection
04:39am, Wednesday, 26'th Feb 2025
Switzerland-based pesticides maker Syngenta said on Wednesday that it has acquired a repository of natural compounds and genetic strains from drugmaker Novartis to further boost development of biologi
Sandoz family foundation offers $3 billion worth of Novartis shares
01:55pm, Tuesday, 25'th Feb 2025
Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss pharmaceutical firm Novartis to raise up to $3 billion in an accelerated bookbuil
Here's Why Novartis (NVS) is a Strong Momentum Stock
10:50am, Tuesday, 25'th Feb 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novartis Invests $7.5M to Promote Early Prostate Cancer Testing in Vulnerable Communities
07:41am, Thursday, 20'th Feb 2025
Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for prostate cancer in vulnerable communities.
Novartis: Strong Execution With A P/E Discount
12:02am, Sunday, 16'th Feb 2025
Q4 2024 results exceeded expectations with 16% net sales growth and a 55% increase in operating income, supporting Novartis' EPS growth trajectory. The acquisition of Anthos Therapeutics and strategic
Novartis: Just What The Doctor Ordered
07:30am, Friday, 14'th Feb 2025
Novartis' robust drug pipeline and strong financials, including an AA- credit rating, support an 11% annual return expectation by 2027. The company's diverse blockbuster portfolio and strategic cost m
Novartis to buy Anthos Therapeutics in $3.1bn deal
03:27am, Tuesday, 11'th Feb 2025
Novartis AG (ADR) (NYSE:NVS) has agreed to buy Anthos Therapeutics in a deal worth up to $3.1 billion. The Swiss drugmaker will pay $925 million upfront, with potential milestone payments of $2.15 bi
Novartis agrees to acquire Anthos for up to $3.1 bln
01:41am, Tuesday, 11'th Feb 2025
Novartis has agreed to acquire Anthos Therapeutics, a developer of a new generation of blood thinners it launched five years ago with backing from the Swiss pharmaceutical giant.
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
01:15am, Tuesday, 11'th Feb 2025
Basel, February 11, 2025 – Novartis today announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical compa
Novartis Rises 5% Since Q4 Earnings: How Should You Play the Stock?
10:51am, Thursday, 06'th Feb 2025
NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors already owning the stock can stay invested.
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
10:51am, Thursday, 06'th Feb 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Novartis (NVS) is a Strong Value Stock
10:41am, Wednesday, 05'th Feb 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
08:32am, Monday, 03'rd Feb 2025
If there were an official hierarchy of qualities that dividend seekers should consider before investing in a stock, a company's underlying business would almost certainly come ahead of its yield. Howe
Novartis is considering further acquisitions to drive growth, CEO says
12:30am, Monday, 03'rd Feb 2025
Novartis CEO Vas Narasimhan weighs in on the impact of the new U.S. administration and artificial intelligence on the pharmaceutical industry, as well as the possibility of further acquisitions.
Novartis Posts Q4 Earnings and Sales Beat, Shares Gain
02:21pm, Friday, 31'st Jan 2025
NVS' fourth-quarter earnings and sales beat estimates. Based on the strong momentum of the company?
